Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis

Abstract

Objective: To evaluate the spectrum of comorbidities and its impact on the clinical outcome in patients with coronavirus disease 2019 . Design: Retrospective case studiesSetting: 575 hospitals in 31 province/autonomous regions/provincial municipalities across China Participants: 1,590 laboratory-confirmed hospitalized patients. Main outcomes and measures: Epidemiological and clinical variables (in particular, comorbidities)were extracted from medical charts. The disease severity was categorized based on the American Thoracic Society guidelines for community-acquired pneumonia. The primary endpoint was the composite endpoints, which consisted of the admission to intensive care unit (ICU), or invasive ventilation, or death. The risk of reaching to the composite endpoints was compared among patients with COVID-19 according to the presence and number of comorbidities.Results: Of the 1,590 cases, the mean age was 48.9 years. 686 patients (42.7%) were females. 647 (40.7%) patients were managed inside Hubei province, and 1,334 (83.9%) patients had a contact history of Wuhan city. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints. 399 (25.1%) reported having at least one comorbidity. : medRxiv preprint 5 malignancy and immunodeficiency, respectively. 130 (8.2%) patients reported having two or more comorbidities. Patients with two or more comorbidities had significantly escalated risks of reaching to the composite endpoint compared with those who had a single comorbidity, and even more so as compared with those without (all P<0.05). After adjusting for age and smoking status, patients with COPD (HR 2.681, 95%CI 1.424-5.048), diabetes (HR 1.59, 95%CI 1.03-2.45), hypertension (HR 1.58, 95%CI 1.07-2.32) and malignancy (HR 3.50, 95%CI 1.60-7.64) were more likely to reach to the composite endpoints than those without. As compared with patients without comorbidity, the HR (95%CI) was 1.79 (95%CI 1.16-2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61-4.17) among patients with two or more comorbidities. Conclusion:Comorbidities are present in around one fourth of patients with COVID-19 in China, and predispose to poorer clinical outcomes. FUNDING: Supported by National Health Commission, Department of Science and Technology of Guangdong Province. The funder had no role in the conduct of the study.

A Multicenter Study of Coronavirus Disease 2019 Outcomes of Cancer Patients in Wuhan, China

“…It may a result of immune compromising effect led by anticancer treatments. [12][13][14] Noteworthy, this study showed that lung cancer was the most common cancer type (accounted for 22.4%), which may have higher susceptibility SARS-CoV-2 infection than other type cancers. There may be two main reasons: (1) lung cancer accounts for a large .…”

Influenza-associated pneumonia as reference to assess seriousness of coronavirus disease (COVID-19)

“…illnesses [16]. But severity in younger adults below 60 years and in patients without chronic preconditions appears to be higher in COVID-19 patients than in pneumonia patients usually seen during the influenza season.…”

Prevention and therapy of COVID-19 via exogenous estrogen treatment for both male and female patients

“…The investigators established that 399 patients with one additional disease had a 79% greater chance for needing intensive care or a respirator assistance as well as for dying. In addition, 130 patients having two or more additional diseases exhibited 2.5 times higher risk for ARDS or dying [23].…”

“…People with pre-existing diseases are more likely to get seriously ill from COVID-19, and men debilitated by chronic illnesses, such as chronic heart disease and type-2 diabetes exhibit a much higher mortality rate [23]. In China, researchers analyzed the data of 1,590 patients with laboratory confirmed COVID-19 infection.…”